Printer Friendly

US subsidiary of Lundbeck launches Northera (droxidopa) capsules in US.

M2 PHARMA-September 4, 2014-US subsidiary of Lundbeck launches Northera (droxidopa) capsules in US

(C)2014 M2 COMMUNICATIONS

The United States subsidiary of Lundbeck, a Danish global pharmaceutical company, has introduced Northera (droxidopa) capsules in the USA, it was reported yesterday.

The product is to be used for the treatment of neurogenic orthostatic hypotension, for which it has received approval from the US Food and Drug Administration. It is indicated to treat orthostatic dizziness, lightheadedness in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure, dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.

Lundbeck US president, Staffan Schuberg, stated that for people living with symptomatic neurogenic orthostatic hypotension, the availability of Northera is likely to offer a new treatment option to discuss with their healthcare provider.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 4, 2014
Words:138
Previous Article:EMD Serono Research and Development Institute signs collaborative research agreement with Massachusetts General Hospital.
Next Article:Macrocure completes patient enrolment in double-blind, Phase III clinical trial of CureXcell.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters